Our portfolio companies work tirelessly to innovate, develop and commercialize products and platform technologies for the prevention, diagnosis and treatment of significant diseases.
Covagen AG developed next-generation protein drugs for inflammatory diseases and cancer using its proprietary protein engineering technology. Covagen AG was acquired by J&J in 2014.
First Investment October 2009 | Seed
ExitAugust 2014 | Acquisition
FerroKin Biosciences developed a next-generation iron chelator for the treatment of iron overload in patients with transfusion-dependent anemia. FerroKin was acquired by Shire Plc in 2012.
San Carlos, CA
First Investment December 2008 | Series A
ExitMarch 2012 | Acquisition
F-star is a clinical-stage company focused on developing bispecific antibody therapeutics. F-star’s lead program is a LAG-3 / PD-L1 bispecific antibody.
Cambridge, UK and Vienna, Austria
First InvestmentJanuary 2010 | Series A Extension
Forge Therapeutics uses a novel drug discovery platform to identify and develop first-in-class therapeutics against metalloprotein drug targets.
San Diego, CA
First Investment April 2017 | Series A
Genkyotex is developing orally available small molecule therapeutics that selectively inhibit NOX enzymes to treat multiple diseases.
First Investment May 2011 | Series C
Exit April 2014 | IPO
Genocea Biosciences uses its proprietary platform for the rapid discovery of T-cell antigens to develop novel vaccines for oncology and infectious disease.
First InvestmentJanuary 2011 | Series B
ExitFebruary 2014 | IPO
Intradigm Corporation developed RNA interference therapeutics for the treatment of serious diseases, and merged with Silence Therapeutics in December 2009.
Palo Alto, CA
First Investment September 2008 | Series B
ExitDecember 2009 | Merger/IPO
miRagen Therapeutics focuses on the discovery and development of innovative microRNA-targeting therapies in disease areas of high unmet medical need.
First Investment November 2015 | Series C
ExitFebruary 2017 | IPO
PharmEste s.r.l. developed transient receptor potential (TRP) channel therapeutics for the treatment of neuropathic pain, overactive bladder, and other TRP-mediated diseases.
ExitSeptember 2014 | Closed
Pronota NV was a diagnostics company focused on low abundance protein biomarkers and antibody-free protein assay development. Pronota merged with a division of Biocartis in 2014 to form MyCartis.
First Investment October 2009 | Series B
ExitSeptember 2014 | Merger
QurAlis is focused on the discovery and development of new therapeutics for ALS, targeting excitotoxicity, TBK1 autophagy, and other novel mechanisms.
First Investment April 2018 | Seed
Ribometrix has an innovative platform to discover and develop small molecule therapeutics for RNA targets, built on the SHAPE-MaP technology initially developed by its founders.
First Investment October 2017 | Seed
Rigontec was a biopharmaceutical company targeting RIG-I for the immune-mediated treatment of cancer and viral diseases. Rigontec was acquired by Merck in 2017.
First Investment August 2015 | Series A
ExitSeptember 2017 | Acquisition
Sonde is developing a voice-based technology platform to monitor and diagnose psychological and physical medical conditions.
First Investment April 2019 | Series A
Syndexa developed novel drugs that targeted the interface between inflammatory and metabolic pathways, using a screening technology to target adaptive ER responses.
First Investment December 2011 | Series B1
Thrasos Therapeutics is a clinical-stage company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease.
First Investment October 2012 | Series C